Twin Tree Management
ALXN

Twin Tree Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Twin Tree Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-36,182
Closed -$5.65M – 1697
2020
Q4 		$5.65M Buy
36,182
+16,274
+82% +$2.09M 0.02% 587
2020
Q3 		$2.28M Sell
19,908
-38,750
-66% -$4.18M 0.01% 742
2020
Q2 		$6.58M Sell
58,658
-111,039
-65% -$11.8M 0.03% 577
2020
Q1 		$15.2M Buy
169,697
+154,085
+987% +$15.1M 0.07% 233
2019
Q4 		$1.69M Buy
+15,612
New +$1.67M 0.01% 761
2019
Q2 		– Sell
-3,605
Closed -$465K – 1656
2019
Q1 		$487K Sell
3,605
-58,625
-94% -$7.29M ﹤0.01% 953
2018
Q4 		$6.06M Buy
62,230
+53,905
+648% +$6.37M 0.04% 450
2018
Q3 		$1.16M Sell
8,325
-4,395
-35% -$551K 0.01% 693
2018
Q2 		$1.58M Buy
+12,720
New +$1.49M 0.01% 689
2018
Q1 		– Sell
-78,195
Closed -$9.35M – 1375
2017
Q4 		$9.35M Buy
78,195
+55,573
+246% +$6.77M 0.07% 252
2017
Q3 		$3.17M Buy
+22,622
New +$3.07M 0.03% 481
2017
Q2 		– Sell
-2,129
Closed -$248K – 1199
2017
Q1 		$258K Buy
+2,129
New +$274K ﹤0.01% 824
2016
Q3 		– Sell
-24,119
Closed -$3.1M – 1391
2016
Q2 		$2.82M Buy
+24,119
New +$3.42M 0.04% 392
2016
Q1 		– Sell
-6,951
Closed -$1.33M – 1563
2015
Q4 		$1.33M Buy
6,951
+3,450
+99% +$603K 0.03% 550
2015
Q3 		$548K Buy
+3,501
New +$639K 0.01% 751
2015
Q2 		– Sell
-6,281
Closed -$1.08M – 1489
2015
Q1 		$1.09M Buy
6,281
+906
+17% +$164K 0.03% 567
2014
Q4 		$995K Buy
5,375
+2,641
+97% +$489K 0.03% 590
2014
Q3 		$453K Sell
2,734
-4,911
-64% -$806K 0.01% 727
2014
Q2 		$1.2M Buy
+7,645
New +$1.21M 0.03% 543
2014
Q1 		– Sell
-2,123
Closed -$338K – 1081
2013
Q4 		$282K Buy
+2,123
New +$255K 0.01% 800

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Twin Tree Management's ALXN Position: Q1 2021 in Review

Twin Tree Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 36,182 shares — an estimated $5.65M sold.

Twin Tree Management first reported a position in ALXN in Q4 2013 and held it in 20 quarters. The position peaked at $15.2M in Q1 2020. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Twin Tree Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Twin Tree Management sold 36,182 Alexion Pharmaceuticals shares in Q1 2021, an estimated $5.65M.
  • Twin Tree Management first reported a position in Alexion Pharmaceuticals in Q4 2013 and held it in 20 quarters.
  • Twin Tree Management's Alexion Pharmaceuticals position peaked at $15.2M in Q1 2020.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Twin Tree Management's 13F filing for Q1 2021, filed 17 May 2021.